Table 2.
Summary of published articles retrieved from Pubmed (2017–2018) regarding the role of DNA methylation in non-invasive diagnosis of liver cancer.
| DNA Alterations. | Gene | Circulating Free DNA / Number of Cases (%) | Reference |
|---|---|---|---|
| Hypermethylation | APC | 36/98 (36.7) | [16] |
| APC | 47 /3 57 (13) | [17] | |
| BVES | 29/98 (29.6) | [16] | |
| COX2 | — | [17] | |
| CDKN2A | 50/237 (21.3) | [18] | |
| GSTP1 | 17/98 (17.3) | [16] | |
| HOXA9 | 20/98 (20.4) | [16] | |
| IGFBP7 | 5.33% | [19] | |
| P16 | 85/119 (71.43) | [20] | |
| HCCS1 | 75/120 (62.5) | [21] | |
| RASSF1A | 51/98 (52.0) | [16] | |
| RASSF1A | 77/105 (73.3) | [22] | |
| RASSF1A | 21/237 (8.9) | [18] | |
| SFRP1 | 73/119 (61.34) | [20] | |
| SOCS3 | 23/48 (47.91) | [23] | |
| STEAP4 | 30/237 (13) | [18] | |
| TBX2 | 179/237 (75.5) | [18] | |
| TIMP3 | 11/98 (11.2) | [16] | |
| VIM | 31/237 (13.1) | [18] | |
| ZNF154 | 135/237 (60.3) | [18] | |
| Hypomethylation | LINE-1 | 80/119 (67.23) | [20] |
| LINE-1 | 70/105 (66.7) | [22] |